Ocumension Therapeutics
Research Ocumension Therapeutics (1477.HK) on Bullrun: market cap HKD 3.95B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1477.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 3.95B
- Financial periodFY2025
- RevenueCNY 804.35M
- Revenue growth92.7%
- Net income-CNY 158.82M
- Free cash flow-CNY 358.65M
- Gross margin44.9%
Valuation Snapshot
latest market cap is HKD 3.95B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 804.35M | -CNY 158.82M | -CNY 358.65M | 44.9% | -0.2 | CNY 377.46M | CNY 187.54M | CNY 3.68B |
| FY2024 | CNY 417.31M | -CNY 268.27M | -CNY 408.97M | 53.9% | -0.39 | CNY 729.21M | CNY 25.78M | CNY 3.77B |
| FY2023 | CNY 246.37M | -CNY 379.79M | -CNY 539.79M | 58.6% | -0.59 | CNY 842.84M | CNY 137.98M | CNY 2.92B |
| FY2022 | CNY 158.96M | -CNY 402.64M | -CNY 510.66M | 64.7% | -0.64 | CNY 1.17B | CNY 29.58M | CNY 2.75B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.95B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ocumension Therapeutics's market cap?
Ocumension Therapeutics's market capitalization is HKD 3.95B.
What does Ocumension Therapeutics do?
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing.